Jinali Dhebariya

Are you interested in learning more about #QPS #bioanalysis capabilities? Get an inside look at the QPS laboratories in this short video. To learn more, visit https://shorturl.at/asPrS or email [email protected]. 

7

Watch Bharat Vadilal Parekh as he shares the four key factors — Expand, Empower, Evaluate, Engage — that have fueled his successful 38-year career. Learn how you can apply these principles to your own practice.

1

🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!

3

Download this resource from Charles River Laboratories to learn recommendations for qPCR/dPCR assay design, validation and method development considerations, while comparing the pros and cons of each technology for applications including biodistribution, viral shedding and gene expression analysis. Check it out >>> https://hubs.ly/Q02TYB6R0

7

Our CSO Graeme Smith recently presented our latest advancements in targeting DNA Polymerase Theta (Polθ) at the Dana Farber Center for BRCA & Related Genes Annual Scientific Symposium. The symposium fostered invaluable exchanges on cutting-edge research and emerging clinical data. Polθ is a critical enzyme predominantly active in cancer cells, supporting a DNA repair mechanism essential for tumor survival. Our lead clinical candidate, ART6043, is specifically designed to inhibit Polθ and disrupt this cancer-dependent repair pathway while sparing healthy cells. By targeting this unique vulnerability, ART6043 has demonstrated potential in preclinical models to enhance the efficacy of other therapies like PARP inhibitors and offer promising strategies for tackling aggressive or treatment-resistant cancers. Learn more about our progress here: https://lnkd.in/eep6PUhH. #OncologyInnovation #PolTheta #CancerResearch #DrugDevelopment 

129

1 Comment

CMC Strategies With CDMOs: Ensuring CQAs For Oligos And Peptides https://lnkd.in/eTD-FgBf - By Kishore Hotha, PhD, MBA, Dr.Hotha's Life Sciences LLC Developing a practical chemistry, manufacturing, and controls (CMC) strategy for advanced molecule therapies demands a shift in approach — focusing on precision, driving innovation, and fostering strong collaborations. 

7

In an recent interview with SelectScience®, study author Karina Eterovic, MSc, PhD, NYS CoQ, R&D Director of Oncology Diagnostics at Eurofins Viracor BioPharma Services, discussed the complex interplay between clonal hematopoiesis (CH) and cancer genomics, in the context of precision of oncology therapy development, cancer diagnosis and treatment. She shared the results of a recent study that emphasize the potential need to integrate routine germline sequencing into clinical practice to prevent the misclassification of CH aberrations. Findings identified somatic CH mutations in a substantial subset of patients with advanced solid tumors. This has implications for accurate treatment decisions in cancer patients, as distinguishing between tumor-derived mutations and CH mutations is crucial. Read more here: https://lnkd.in/ezM6KXWx #onocologyresearch #cancer #genomics #eurofins #testingforlife #biopharma Eurofins Bioanalytical Services Eurofins Central Laboratory Eurofins Clinical Trial Supplies

44

A strategic approach that ensures the high quality of drugs by employing statistical and risk-management methodology, Quality by Design can be applied for effective and efficient tech transfer and process characterization. Learn more from our Senior Director of the Multi Modality MSAT Team Youngsun Kim in this recent webinar. https://lnkd.in/eFT7w6NV #QualityByDesign #QbD #TechTransfer #ProcessCharacterization

31

Watch this #oncotargetshort #video about the #news feature #published in Volume 15, entitled, "Advancements in cell-penetrating monoclonal antibody treatment." UConn School of Pharmacy https://lnkd.in/ex4_phcQ #cancer #antibodies #cells #oncology #research #openaccess #openscience #peerreview #journal #publication #publishing #trending #meded

1

Key Clinical Compound Updates from November 2024 | https://lnkd.in/gKiaSfUa This summary of major clinical updates from November covers FDA approvals, the initiation of new clinical trials, notable trial outcomes for key drug candidates, and news on paused and discontinued trials and programs. The highlights feature exciting data on GLP-1-based therapeutics for weight loss and metabolic disorders, promising results for a potential first-in-class oral lipoprotein(a) inhibitor, and disappointing performance of a schizophrenia drug with a promising mechanism. Read more here: https://lnkd.in/gKiaSfUa

87

4 Comments

ASCO2024 Updates: Soki Kashima on Single-Cell RNA Sequencing in RCC American Society of Clinical Oncology (ASCO) https://lnkd.in/eizJX3Jk #ASCO #ASCO24 #ASCO24Updates #Cancer #OncoDaily #OncoDailyASCO24Updates #Oncology #Medicine #Health

21

📢 FDA Announces Final Guidance on M12 Drug Interaction Studies The FDA has released the final guidance for "M12 Drug Interaction Studies" and a supplemental Q&A document. Prepared by the ICH, this guidance offers recommendations on evaluating enzyme and transporter-mediated pharmacokinetic drug-drug interactions for investigational drugs. The aim is to harmonize regional guidelines for designing, conducting, and interpreting in vitro and clinical evaluations of drug interactions. This guidance replaces the draft issued on August 29, 2022. Know more - https://lnkd.in/eq4RMH97 #DrugDevelopment #Pharmacokinetics #FDA #ICH #DrugInteractions #clinicalstudy #pharmacovigilance

7

During our recent webinar with NysnoBio, titled “Discovery to hope: Advancing vector-based #genetherapies for #Parkinsonsdisease,” Dr. Pouria Motevalian, Director of Viral Vector Process Development at Thermo Fisher Scientific, addressed the following question: "How does Thermo Fisher Scientific meet the demand for accelerated #genetherapy development timelines?" In his response, Dr. Motevalian attributed our success to our #high-throughput processes and #analyticaldevelopment technologies. This approach enables us to optimize #genetherapy development, ensuring quicker progress without compromising #productquality. To watch the full webinar, click here: http://spr.ly/6041gO6pH

51

Metabolite profile and in vitro cholinesterase inhibitory activity of extract and fractions of Aaptos suberitoides. https://ow.ly/ANMm50Qx3pk #Pharmacy #Pharmacology #NaturalProduct #NCS

2